Warner-lambert Company

Pfizer Corporation

Suzanne Ross Kesten

Lawrence D Wise

David Juergen Wustrow

Stephen J Johnson

David T Connor

Paul C Unangst

Thomas R Belliotti

Shelly Ann Glase

Jonathan L Wright

Steven Robert Miller

Scott E Lazerwith

Lijuan Jane Wang

Nancy C Lan

Lain-Yen Hu

Douglas Scott Johnson

Clifton J Blankley

Todd Robert Ryder

Ravindra B Upasani

Marvin Jay Meyers

Huangshu Lei

Cory Michael Stiff

Thomas A Pugsley

Lorraine Kathleen Fay

Mark Anthony Morris

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

Biaryl ether urea compounds

The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases

Novel 4-Benzyl piperidine alkylsulfoxide heterocycles are disclosed and their use as subtype selective NMDA receptor antagonists, particularly for the treatment of Parkinson's disease, most preferably in combination with L-DOPA.

4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists

This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.

Compounds and method of treating psychosis and schizophrenia

Substituted cyclohexylamines as central nervous systems agents

This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.

Dopamine D4 receptor antagonists

Coumarin dopamine D4 receptor antagonists

This invention relates to compounds that are antagonists of dopamine D4 receptors having Formula I below ##STR1## This invention also relates to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.

Tetrahydroquinoxaline dopamine D4 receptor antagonists

Neurotensin antagonists are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and as agents to treat Parkinson's disease and gastrointestinal disorders.

Neurotensin antagonists

Naphthalamides are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and as agents for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders.

Naphthalamides as central nervous system agents

Growing community of inventors

Ann Arbor, MI, United States of America

Suzanne Ross Kesten